Flowflex is authorized by FDA under an EUA and has the CE Mark for self-testing, is available in more than 100 countries around the world and is used by the National Health Service (NHS) in the United Kingdom as well as by governments and medical associations in the United States, Singapore, Australia, and many more
Flowflex Antigen Rapid Test Kit. (Credit: PRNewswire / Prenetics Group Limited)
Prenetics Group Limited (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, announced today that it has partnered with ACON Bio to launch the Flowflex™ SARS-CoV-2 Antigen Rapid Test Kit (“Flowflex™”) in Hong Kong.
The affordable and easy-to-use COVID-19 self-testing solution is the most accurate antigen test kit in the market*. FlowFlex™ is well-equipped with the latest patented technology and provides results in just 15 minutes with 98.8% accuracy.
*Flowflex™ is the most accurate antigen test in the market in both clinical sensitivity and specificity, and also in the detection of Omicron, based on two independent validation studies:
Independent Nationwide Clinical Sensitivity and Specificity Study with 46 rapid antigen tests – Led by Copenhagen University Hospital, Denmark. In summary, FlowFlex™ achieved 94% sensitivity and 100% specificity in the study, outperforming all test kits, including from Roche and Abbott.
Independent Clinical Omicron and Delta Sensitivity Study with 7 antigen tests – Led by the University of Geneva, Switzerland, and was supported by the Swiss National Science Foundation and the Foundation for Innovative New Diagnostics, an World Health Organization Collaborating Centre. In summary, FlowFlex™ achieved 91.2% and 88.9% sensitivity, respectively for the detection of Delta and Omicron variants, outperforming all antigen test kits.
Flowflex™ is authorized by FDA under an EUA and has the CE Mark for self-testing, is available in more than 100 countries around the world and is used by the National Health Service (NHS) in the United Kingdom as well as by governments and medical associations in the United States, Singapore, Australia, and many more. FlowFlex™ is suitable for use in individuals with and without COVID-19 symptoms, and for children as young as two years old.
FlowFlex™, which received its FDA EUA authorization* on Oct 4th, 2021, was instrumental to doubling the supply of rapid antigen test kits in the United States, having ramped up production to more than 200m test kits on a monthly basis.
“We are grateful to partner with ACON Bio, given the urgent need for rapid testing in Hong Kong. With our partnership, we aim to supply millions of testing kits and make it the most affordable FDA EUA authorized rapid test in Hong Kong,” said Danny Yeung, CEO and Co-Founder, Prenetics. “By providing near instant results without the need for specialist equipment or to visit testing facilities, Flowflex™ can provide reassurance before visiting family and friends, particularly those who are more vulnerable.”
To make it much more accessible to the general public, Flowflex™ will be priced significantly below the market average of HKD120 for other FDA EUA approved rapid testing solutions in Hong Kong.
Source: Company Press Release